Family Planning NSW is a partner in the international study 'Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5 mg) and 17ß-estradiol (1.5 mg)' (PRO-E2 study).
The main outcome the study is assessing is the risk of venous thromboembolism. This is an exciting study that will produce "real world" data that may help to inform future practice. Recruitment for the study has now closed.
Women who were newly prescribed Zoely® or a levonorgestrel-containing combined oral contraceptive pill were invited to participate in this study. T
This post authorisation, regulatory study in twelve countries is recruiting 101,000 women. It is being run in Australia by Family Planning NSW in collaboration with the Berlin Center for Epidemiology and Health Research (ZEG) in Berlin, Germany.
For any questions about the PROE2 study, please contact researchcentre@fpnsw.org.au